Evidence on the Link between Respiratory Syncytial Virus Infection in Early Life and Chronic Obstructive Lung Diseases
There is growing evidence in medical literature to support an association between early-life respiratory syncytial virus lower respiratory tract-lower respiratory tract infection (RSV-LRTI) and recurrent wheezing/asthma-like symptoms. It has been estimated that children with a history of RSV-LRTI have a 2- to 12-fold higher risk of developing asthma. The connection between RSV infection and a developmental trajectory of reduced lung function remains throughout adolescence and early adulthood, suggesting a possible role for RSV even in the inception of chronic obstructive pulmonary disease. That is why the postnatal period appears to offer a specific window of opportunity for early intervention to prevent chronic obstructive lung diseases. The mechanisms by which RSV contributes to the onset of wheezing/asthma and lung function impairment are not fully understood but appear to relate to injury caused directly by the virus and/or to pre-existing predisposing factors. While awaiting a deeper understanding of the association between RSV and chronic lung diseases, the crucial role of pediatricians and physicians is to develop strategies to prevent RSV infections to try and protect children's lifelong respiratory health.
Several evidence suggest a link between RSV infection in early life and wheezing/asthma development.
RSV infection appears to have long term respiratory effects.
The prevention of RSV infections could reduce the incidence of chronic obstructive respiratory diseases.
Keywordsrespiratory syncytial virus - wheezing - asthma - chronic obstructive pulmonary disease - prevention
09 August 2020 (online)
© 2020. Thieme. All rights reserved.
Thieme Medical Publishers
333 Seventh Avenue, New York, NY 10001, USA.
- 1 Mazur NI, Martinón-Torres F, Baraldi E. , et al; Respiratory Syncytial Virus Network (ReSViNET). Lower respiratory tract infection caused by respiratory syncytial virus: current management and new therapeutics. Lancet Respir Med 2015; 3 (11) 888-900
- 2 Feldman AS, He Y, Moore ML, Hershenson MB, Hartert TV. Toward primary prevention of asthma. Reviewing the evidence for early-life respiratory viral infections as modifiable risk factors to prevent childhood asthma. Am J Respir Crit Care Med 2015; 191 (01) 34-44
- 3 Fauroux B, Simões EAF, Checchia PA. , et al. The burden and long-term respiratory morbidity associated with respiratory syncytial virus infection in early childhood. Infect Dis Ther 2017; 6 (02) 173-197
- 4 Berry CE, Billheimer D, Jenkins IC. , et al. A distinct low lung function trajectory from childhood to the fourth decade of life. Am J Respir Crit Care Med 2016; 194 (05) 607-612
- 5 Carraro S, Scheltema N, Bont L, Baraldi E. Early-life origins of chronic respiratory diseases: understanding and promoting healthy ageing. Eur Respir J 2014; 44 (06) 1682-1696
- 6 Wittig HJ, Glaser J. The relationship between bronchiolitis and childhood asthma; a follow-up study of 100 cases of bronchiolitis. J Allergy 1959; 30 (01) 19-23
- 7 Verwey C, Nunes MC, Dangor Z, Madhi SA. Pulmonary function sequelae after respiratory syncytial virus lower respiratory tract infection in children: a systematic review. Pediatr Pulmonol 2020; 55 (07) 1567-1583
- 8 Régnier SA, Huels J. Association between respiratory syncytial virus hospitalizations in infants and respiratory sequelae: systematic review and meta-analysis. Pediatr Infect Dis J 2013; 32 (08) 820-826
- 9 Shi T, Ooi Y, Zaw EM. , et al; RESCEU Investigators. Association between respiratory syncytial virus-associated acute lower respiratory infection in early life and recurrent wheeze and asthma in later childhood. J Infect Dis 2019; jiz311 (e-pub ahead of print) DOI: Doi: 10.1093/infdis/jiz311.
- 10 Stein RT, Sherrill D, Morgan WJ. , et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet 1999; 354 (9178): 541-545
- 11 Sigurs N, Aljassim F, Kjellman B. , et al. Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life. Thorax 2010; 65 (12) 1045-1052
- 12 Bacharier LB, Cohen R, Schweiger T. , et al. Determinants of asthma after severe respiratory syncytial virus bronchiolitis. J Allergy Clin Immunol 2012; 130 (01) 91-100.e3
- 13 Lu S, Hartert TV, Everard ML. , et al. Predictors of asthma following severe respiratory syncytial virus (RSV) bronchiolitis in early childhood. Pediatr Pulmonol 2016; 51 (12) 1382-1392
- 14 Marlow R, Finn A, Henderson J. Assessing the association between bronchiolitis in infancy and recurrent wheeze: a whole English birth cohort case-control study. Thorax 2019; 74 (05) 503-505
- 15 Coutts J, Fullarton J, Morris C. , et al. Association between respiratory syncytial virus hospitalization in infancy and childhood asthma. Pediatr Pulmonol 2020; 55 (05) 1104-1110
- 16 Backman K, Piippo-Savolainen E, Ollikainen H, Koskela H, Korppi M. Increased asthma risk and impaired quality of life after bronchiolitis or pneumonia in infancy. Pediatr Pulmonol 2014; 49 (04) 318-325
- 17 Carroll KN, Wu P, Gebretsadik T. , et al. The severity-dependent relationship of infant bronchiolitis on the risk and morbidity of early childhood asthma. J Allergy Clin Immunol 2009; 123 (05) 1055-1061 , 1061.e1
- 18 Esteban I, Stein RT, Polack FP. A durable relationship: respiratory syncytial virus bronchiolitis and asthma past their golden anniversary. Vaccines (Basel) 2020; 8 (02) 201
- 19 Barlotta A, Pirillo P, Stocchero M. , et al. Metabolomic profiling of infants with recurrent wheezing after bronchiolitis. J Infect Dis 2019; 219 (08) 1216-1223
- 20 Blanken MO, Rovers MM, Molenaar JM. , et al; Dutch RSV Neonatal Network. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med 2013; 368 (19) 1791-1799
- 21 Scheltema NM, Nibbelke EE, Pouw J. , et al. Respiratory syncytial virus prevention and asthma in healthy preterm infants: a randomised controlled trial. Lancet Respir Med 2018; 6 (04) 257-264
- 22 Mochizuki H, Kusuda S, Okada K, Yoshihara S, Furuya H, Simões EAF. Scientific Committee for Elucidation of Infantile Asthma. Palivizumab prophylaxis in preterm infants and subsequent recurrent wheezing: six-year follow-up study. Am J Respir Crit Care Med 2017; 196 (01) 29-38
- 23 Tripp RA, Power UF, Openshaw PJM, Kauvar LM. Respiratory syncytial virus: targeting the G protein provides a new approach for an old problem. J Virol 2018; 92 (03) e01302-17
- 24 European Medicines Agency. EPAR for Synagis. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/synagis . Accessed June 5, 2020
- 25 Resch B. Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection. Hum Vaccin Immunother 2017; 13 (09) 2138-2149
- 26 Press release, 21 December 2010. AstraZeneca discontinues development of motavizumab for RSV prophylaxis indication. Available at: https://www.astrazeneca.com/media-centre/press-releases/2010/AstraZeneca-discontinues-motavizumab-RSV-21122010.html# . Accessed June 5, 2020
- 27 Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV. (Respiratory syncytial virus) infection in preterm infants. Available at: https://clinicaltrials.gov/ct2/show/NCT02325791 . Accessed June 5, 2020
- 28 Press release, 14 August 2017. Regeneron to discontinue development of suptavumab for respiratory syncytial virus. Available at: https://investor.regeneron.com/news-releases/news-release-details/regeneron-discontinue-development-suptavumab-respiratory/ . Accessed June 5, 2020
- 29 Safety, tolerability, and pharmacokinetics of MK-1654 in infants (MK-1654–002). Available at: https://www.clinicaltrials.gov/ct2/show/record/NCT03524118 . Accessed June 10, 2020
- 30 A study to evaluate the safety and efficacy of MEDI8897 for the prevention of medically attended RSV LRTI in healthy preterm infants. (MEDI8897 Ph2b). Available at: https://clinicaltrials.gov/ct2/show/NCT02878330 . Accessed June 5, 2020
- 31 A study to evaluate the safety of MEDI8897 for the prevention of medically attended respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI) in high-risk children. Available at: https://clinicaltrials.gov/ct2/show/NCT03959488 . Accessed June 5, 2020
- 32 A study to evaluate the safety and efficacy of MEDI8897 for the prevention of medically attended RSV LRTI in healthy late preterm and term infants (MELODY). Available at: https://clinicaltrials.gov/ct2/show/NCT03979313 . Accessed June 5, 2020